Abstract |
The clinical efficiency of mitigating contact dermatitis with a Ginkgo biloba extract and carboxymethyl-beta-1,3-glucan formulation was investigated in a double-blind versus placebo study using 22 subjects (Caucasian women aged 22-55 years) with allergic contact dermatitis from various substances in the European standard series. The formulation was applied to intact skin 2X a day for 2 weeks ("in use" application) prior to a single application of a selected contact allergen under a Finn Chamber for 24 h. Readings were carried out in a blind study by a dermatologist 2 and 3 days after patch removal. Representative photographs were taken of treated, placebo and untreated test areas. 68.2% of the panelists showed significantly reduced skin reactivity (p = 0.037*) on the treated site 2 days after patch removal, versus untreated and/or placebo sites. This finding indicates that the Ginkgo biloba/carboxymethyl-beta-1,3- glucan formulation can mitigate against allergic contact dermatitis.
|
Authors | D Castelli, L Colin, E Camel, G Ries |
Journal | Contact dermatitis
(Contact Dermatitis)
Vol. 38
Issue 3
Pg. 123-6
(Mar 1998)
ISSN: 0105-1873 [Print] England |
PMID | 9536401
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Drug Combinations
- Flavonoids
- Free Radical Scavengers
- Glucans
- Ointments
- Plant Extracts
- beta-Glucans
- Ginkgo biloba extract
- carboxymethyl-beta-1,3-glucan
|
Topics |
- Adult
- Dermatitis, Allergic Contact
(pathology, prevention & control)
- Double-Blind Method
- Drug Combinations
- Female
- Flavonoids
(therapeutic use)
- Free Radical Scavengers
(therapeutic use)
- Ginkgo biloba
- Glucans
(therapeutic use)
- Humans
- Middle Aged
- Ointments
(therapeutic use)
- Patch Tests
- Plant Extracts
- Skin Care
- Treatment Outcome
- beta-Glucans
|